Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
3.
Am Surg ; 87(11): 1704-1712, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1367605

ABSTRACT

In the United States, the nation's health is not an organic outcome. It is not a coincidence that certain groups of people living in the United States experience higher premature death rates or poorer health outcomes than others. For centuries, racial and ethnic as well as geographic differences in health outcomes have been part of the American landscape, so entrenched in society that many people fail to recognize that health inequities were intentionally derived. A national crisis tends to magnify inequities in our society, but even more alarming is the fact that as the country becomes more racially and ethnically diverse in the coming years, the health inequities are projected to worsen if we do not proactively and immediately address them. As we continue to grapple with the lasting impact of the pandemic, it is of vital importance that we utilize this time to acknowledge, understand, and seriously address the health inequities that have historically plagued the country for over 400 years. As the United States works overtime to stem the tide of the COVID-19 pandemic, it must also work equally hard to move in a more equitable, inclusive, and healthier direction, not only because of the more than 83 000 Americans dying prematurely each year but also because of the economic and national security toll it will have if not effectively addressed.


Subject(s)
COVID-19 , Health Equity , Health Inequities , Physician's Role , Racism , COVID-19/epidemiology , Health Equity/statistics & numerical data , Humans , Pandemics , Politics , Population Groups/statistics & numerical data , Racism/prevention & control , Racism/statistics & numerical data , SARS-CoV-2 , Social Determinants of Health/statistics & numerical data , Surgeons , United States/epidemiology
4.
PLoS One ; 16(7): e0254633, 2021.
Article in English | MEDLINE | ID: covidwho-1315889

ABSTRACT

BACKGROUND: Almost 200,000 deaths from COVID-19 were reported in Brazil in 2020. The case fatality rate of a new infectious disease can vary by different risk factors and over time. We analysed the trends and associated factors of COVID-19 case fatality rates in Brazilian public hospital admissions during the first wave of the pandemic. METHODS: A retrospective cohort of all COVID-19-related admissions between epidemiological weeks 10-40 in the Brazilian Public Health System (SUS) was delimited from available reimbursement records. Smoothing time series and survival analyses were conducted to evaluate the trends of hospital case fatality rates (CFR) and the probability of death according to factors such as sex, age, ethnicity, comorbidities, length of stay and ICU use. RESULTS: With 398,063 admissions and 86,452 (21.7%) deaths, the overall age-standardized hospital CFR trend decreased throughout the period, varying from 31.8% (95%CI: 31.2 to 32.5%) in week 10 to 18.2% (95%CI: 17.6 to 18.8%) in week 40. This decreasing trend was observed in all sex, age, ethnic groups, length of stay and ICU admissions. Consistently, later admission (from July to September) was an independent protective factor. Patients 80+ year old had a hazard ratio of 8.18 (95% CI: 7.51 to 8.91). Ethnicity, comorbidities, and ICU need were also associated with the death risk. Although also decreasing, the CFR was always around 40-50% in people who needed an ICU admission. CONCLUSIONS: The overall hospital CFR of COVID-19 has decreased in Brazilian public hospitals during the first wave of the pandemic in 2020. Nevertheless, during the entire period, the CFR was still very high, suggesting the need for improving COVID-19 hospital care in Brazil.


Subject(s)
COVID-19/mortality , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Brazil , COVID-19/epidemiology , Comorbidity , Female , Hospitals, Public/statistics & numerical data , Humans , Male , Middle Aged , Mortality/trends , Patient Admission/statistics & numerical data , Population Groups/statistics & numerical data , Sex Factors , Socioeconomic Factors
5.
PLoS One ; 16(7): e0254635, 2021.
Article in English | MEDLINE | ID: covidwho-1311289

ABSTRACT

BACKGROUND: Statins have anti-inflammatory and immunomodulatory effects that may reduce the severity of coronavirus disease 2019 (COVID-19), in which organ dysfunction is mediated by severe inflammation. Large studies with diverse populations evaluating statin use and outcomes in COVID-19 are lacking. METHODS AND RESULTS: We used data from 10,541 patients hospitalized with COVID-19 through September 2020 at 104 US hospitals enrolled in the American Heart Association's COVID-19 Cardiovascular Disease (CVD) Registry to evaluate the associations between statin use and outcomes. Prior to admission, 42% of subjects (n = 4,449) used statins (7% on statins alone, 35% on statins plus anti-hypertensives). Death (or discharge to hospice) occurred in 2,212 subjects (21%). Outpatient use of statins, either alone or with anti-hypertensives, was associated with a reduced risk of death (adjusted odds ratio [aOR] 0.59, 95% CI 0.50-0.69), adjusting for demographic characteristics, insurance status, hospital site, and concurrent medications by logistic regression. In propensity-matched analyses, use of statins and/or anti-hypertensives was associated with a reduced risk of death among those with a history of CVD and/or hypertension (aOR 0.68, 95% CI 0.58-0.81). An observed 16% reduction in odds of death among those without CVD and/or hypertension was not statistically significant. CONCLUSIONS: Patients taking statins prior to hospitalization for COVID-19 had substantially lower odds of death, primarily among individuals with a history of CVD and/or hypertension. These observations support the continuation and aggressive initiation of statin and anti-hypertensive therapies among patients at risk for COVID-19, if these treatments are indicated based upon underlying medical conditions.


Subject(s)
Antihypertensive Agents/administration & dosage , COVID-19/epidemiology , Cardiovascular Diseases/epidemiology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Registries/statistics & numerical data , Adult , Age Factors , Aged , American Heart Association , Antihypertensive Agents/therapeutic use , COVID-19/mortality , Cardiovascular Diseases/drug therapy , Drug Utilization/statistics & numerical data , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Male , Middle Aged , Mortality/trends , Population Groups/statistics & numerical data , United States
6.
PLoS One ; 16(3): e0239168, 2021.
Article in English | MEDLINE | ID: covidwho-1125199

ABSTRACT

INTRODUCTION: Across the world, the COVID-19 pandemic has disproportionately affected racial and ethnic minorities. How ethnicity affects Indigenous peoples in Mexico is unclear. The aim of this cross-sectional study was to determine the mortality associated with ethnicity, particularly of Indigenous peoples, in a large sample of patients with COVID-19 in Mexico. METHODS: We used open access data from the Mexican Ministry of Health, which includes data of all confirmed COVID-19 cases in the country. We used descriptive statistics to compare differences among different groups of patients. Logistic regression was used to calculate odds ratios while adjusting for confounders. RESULTS: From February 28 to August 3, 2020, a total of 416546 adult patients were diagnosed with COVID-19. Among these, 4178 were Indigenous peoples. Among all patients with COVID-19, whether hospitalized or not, a higher proportion of Indigenous peoples died compared to non-Indigenous people (16.5% vs 11.1%, respectively). Among hospitalized patients, a higher proportion of Indigenous peoples died (37.1%) compared to non-Indigenous peoples (36.3%). Deaths outside the hospital were also higher among Indigenous peoples (3.7% vs 1.7%). A higher proportion of Indigenous peoples died in both the private and public health care sectors. The adjusted odds ratio for COVID-19 mortality among Indigenous peoples with COVID-19 was 1.13 (95% confidence interval 1.03 to 1.24). The adjusted odds ratio for COVID-19 mortality among Indigenous peoples with COVID-19 was higher among those who received only ambulatory care (1.55, 95% confidence interval 1.24 to 1.92). DISCUSSION: In this large sample of patients with COVID-19, the findings suggest that Indigenous peoples in Mexico have a higher risk of death from COVID-19, especially outside the hospital. These findings suggest Indigenous peoples lack access to care more so than non-Indigenous people during the COVID-19 pandemic in Mexico.


Subject(s)
COVID-19/epidemiology , COVID-19/mortality , Healthcare Disparities/ethnology , Adult , Cross-Sectional Studies , Ethnicity/statistics & numerical data , Female , Health Status Disparities , Humans , Indigenous Peoples/statistics & numerical data , Male , Mexico/epidemiology , Middle Aged , Minority Groups/statistics & numerical data , Pandemics , Population Groups/statistics & numerical data , SARS-CoV-2/pathogenicity
8.
J Racial Ethn Health Disparities ; 8(5): 1119-1129, 2021 10.
Article in English | MEDLINE | ID: covidwho-763950

ABSTRACT

The current health, political, and environmental crisis ongoing in Brazil and the advances of the impacts of COVID-19 in traditional populations (as indigenous and quilombolas) are not yet prioritized in the scientific production about the novel coronavirus. We performed spatial correlation analysis to map the clusters and outliers of COVID-19 in South of Brazil to identify indigenous and quilombolas communities impacted right now in the pandemic. We show that communities located nearby metropolitan areas and mid-sized cities are the most impacted by the COVID-19 and the advance of the transmission to inner states may intensify the ongoing historical process of elimination of indigenous and quilombolas people. We call for a global response to the indigenous and quilombolas situation in Brazil, pointing to the need of more analysis in the country.


Subject(s)
COVID-19/epidemiology , Health Status Disparities , Population Groups/statistics & numerical data , Brazil/epidemiology , Cities/epidemiology , Humans , Risk , Spatial Analysis
SELECTION OF CITATIONS
SEARCH DETAIL